Pelareorep

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Retrieved on: 
Friday, September 22, 2023
AMGN, KRAS, Gastrointestinal cancer, Amgen, Optimism, DOR, National Institutes of Health, Bangladesh Technical Education Board, Congress, Patient, Risk, Corr, H. Lee Moffitt Cancer Center & Research Institute, News, Disease, Carcinoma, Oncolytics Biotech, European Hematology Association, Hope, Lung cancer, ONC, Hematology, TSX, Bone marrow, BTC, The Lancet, FDA, Polycythemia, NIH, Safety, Docetaxel, Abstract, Eye, Cancer, NSCLC, PFS, Psoriasis, MD Anderson Cancer Center, Breakthrough therapy, Colorectal cancer, University, Cancer Moonshot, Therapy, ORR, Partnership, CRC, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, SCLC, ASCO, Pelareorep, EHA, Jazz Pharmaceuticals, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Medical imaging, Protagonist, Research

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious "Cancer Moonshot" initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

Key Points: 
  • The oral presentation shared at the event described how they've been testing a treatment for advanced breast cancer, and it's looking very promising.
  • The treatment combines Oncolytics' flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel.
  • Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed.
  • It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Retrieved on: 
Friday, September 22, 2023
AMGN, KRAS, Gastrointestinal cancer, Amgen, Optimism, DOR, National Institutes of Health, Bangladesh Technical Education Board, Congress, Patient, Risk, Corr, H. Lee Moffitt Cancer Center & Research Institute, News, Disease, Carcinoma, Oncolytics Biotech, European Hematology Association, Hope, Lung cancer, ONC, Hematology, TSX, Bone marrow, BTC, The Lancet, FDA, Polycythemia, NIH, Safety, Docetaxel, Abstract, Eye, Cancer, NSCLC, PFS, Psoriasis, MD Anderson Cancer Center, Breakthrough therapy, Colorectal cancer, University, Cancer Moonshot, Therapy, ORR, Partnership, CRC, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, SCLC, ASCO, Pelareorep, EHA, Jazz Pharmaceuticals, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Medical imaging, Protagonist, Research

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious "Cancer Moonshot" initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

Key Points: 
  • The oral presentation shared at the event described how they've been testing a treatment for advanced breast cancer, and it's looking very promising.
  • The treatment combines Oncolytics' flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel.
  • Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed.
  • It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

Retrieved on: 
Wednesday, September 20, 2023
US Foods, Mantle cell lymphoma, IMGN, Congress, Prednisone, Patient, AstraZeneca, Risk, Prostate cancer, Propel, Eli Lilly and Company, Merck, Merck & Co., News, NYSE, Disease, White House, Monarchism in Iran, MRK, Hope, Mutation, ONC, TSX, FDA, Death, Prednisolone, Oncolytics Biotech, Eye, Cancer, ImmunoGen, PFS, BTK, Cancer Moonshot, BRCA, Ovarian cancer, ORR, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, Quality of life, Pelareorep, MCL, Food, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Abemaciclib, Pirtobrutinib

VANCOUVER, British Columbia , Sept. 20, 2023 /PRNewswire/ -- USA News Group - Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their  "Cancer Moonshot" initiative, an ambitious plan to slash cancer rates in half within the next quarter-century. Already, 2023 is brimming with encouraging progress in the biotech sector that is boosting our hope in the battle against cancer. Simplifying the jargon, this includes major breakthroughs in treatments that are prolonging the time before cancer worsens (known as progression-free survival or PFS) and increasing the rate at which patients respond positively to treatment (overall response rate or ORR). This inspiring progress has been led by companies like from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company, ImmunoGen, Inc. (NASDAQ: IMGN), Merck &Co., Inc. (NYSE: MRK), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • Already, 2023 is brimming with encouraging progress in the biotech sector that is boosting our hope in the battle against cancer.
  • The trial, known as BRACELET-1, tested a therapy that combines the company's drug, pelareorep, with a common cancer treatment, paclitaxel.
  • In fact, the risk of the disease getting worse was reduced by an impressive 71% compared to paclitaxel alone, through its progression-free survival (PFS).
  • For patients, this could mean more time to enjoy life without the burden of worsening symptoms.

On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

Retrieved on: 
Wednesday, September 20, 2023
US Foods, Mantle cell lymphoma, IMGN, Congress, Prednisone, Patient, AstraZeneca, Risk, Prostate cancer, Propel, Eli Lilly and Company, Merck, Merck & Co., News, NYSE, Disease, White House, Monarchism in Iran, MRK, Hope, Mutation, ONC, TSX, FDA, Death, Prednisolone, Oncolytics Biotech, Eye, Cancer, ImmunoGen, PFS, BTK, Cancer Moonshot, BRCA, Ovarian cancer, ORR, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, Quality of life, Pelareorep, MCL, Food, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Abemaciclib, Pirtobrutinib

VANCOUVER, British Columbia, Sept. 20, 2023 /PRNewswire/ -- USA News Group - Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their  "Cancer Moonshot" initiative, an ambitious plan to slash cancer rates in half within the next quarter-century. Already, 2023 is brimming with encouraging progress in the biotech sector that is boosting our hope in the battle against cancer. Simplifying the jargon, this includes major breakthroughs in treatments that are prolonging the time before cancer worsens (known as progression-free survival or PFS) and increasing the rate at which patients respond positively to treatment (overall response rate or ORR). This inspiring progress has been led by companies like from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company, ImmunoGen, Inc. (NASDAQ: IMGN), Merck &Co., Inc. (NYSE: MRK), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • Already, 2023 is brimming with encouraging progress in the biotech sector that is boosting our hope in the battle against cancer.
  • The trial, known as BRACELET-1, tested a therapy that combines the company's drug, pelareorep, with a common cancer treatment, paclitaxel.
  • In fact, the risk of the disease getting worse was reduced by an impressive 71% compared to paclitaxel alone, through its progression-free survival (PFS).
  • For patients, this could mean more time to enjoy life without the burden of worsening symptoms.

Pancreatic Cancer Battle Boosted by $200M VC Firm

Retrieved on: 
Tuesday, September 19, 2023
MACK, Rockefeller University, Stanford University, Pancreatic Cancer Action Network, MBA, Congress, Emerson Collective, MD, Patient, BNTX, Fast track (FDA), News, The New York Times, Interview, Ipsen, BioNTech, Mirati Therapeutics, Incyte, ONC, JD, Memorial Sloan Kettering Cancer Center, TSX, Metastasis, FDA, Roche, Pancreatic cancer, Oncolytics Biotech, Cancer, Lung cancer, MIT, Messenger, Mirati, MSK, Partnership, Pelareorep, Irinotecan, Merrimack Pharmaceuticals, American Cancer Society, FTD, Pharmaceutical industry, Genentech, Apple, Yosemite National Park, Research

VANCOUVER, BC, Sept. 19, 2023 /PRNewswire/ -- USA News Group  -  A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT,  Memorial Sloan Kettering Cancer Center and The Rockefeller University. Led by 31-year old Reed Jobs, the new firm dubbed 'Yosemite' appears to be an extension of the legacy left by the founder's father, Steve Jobs, the co-founder of Apple, who died in 2011 from a rare form of pancreatic cancer at the age of only 56. From an investment standpoint, the Global Pancreatic Cancer Market is expected to surpass US$7.4 billion by 2032, growing at a health CAGR of 13.7% along the way. Among the biotech sector's most promising developers of treatments for pancreatic cancer are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Incyte Corporation (NASDAQ:INCY), Mirati Therapeutics, Inc. (NASDAQ:MRTX), and BioNTech SE (NASDAQ:BNTX).

Key Points: 
  • According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic cancer increased by 1% from the previous year to 12%.
  • In terms of targeting pancreatic cancer, the efforts align with the Pancreatic Cancer Action Network (PanCAN), which has been urging advocates from all 50 US states to call on Congress to increase federal funding for pancreatic cancer research.
  • These tests will be for people who have certain kinds of lung cancer, bowel cancer, pancreatic cancer, and other solid tumors, with Mirati providing Incyte with a drug called Adagrasib to use in the study.
  • The tailored neoantigen pancreatic cancer vaccine from BioNTech invoked an immune response in 50% of patients and prevented relapse.

Pancreatic Cancer Battle Boosted by $200M VC Firm

Retrieved on: 
Tuesday, September 19, 2023
MACK, Rockefeller University, Stanford University, Pancreatic Cancer Action Network, MBA, Congress, Emerson Collective, MD, Patient, BNTX, Fast track (FDA), News, The New York Times, Interview, Ipsen, BioNTech, Mirati Therapeutics, Incyte, ONC, JD, Memorial Sloan Kettering Cancer Center, TSX, Metastasis, FDA, Roche, Pancreatic cancer, Oncolytics Biotech, Cancer, Lung cancer, MIT, Messenger, Mirati, MSK, Partnership, Pelareorep, Irinotecan, Merrimack Pharmaceuticals, American Cancer Society, FTD, Pharmaceutical industry, Genentech, Apple, Yosemite National Park, Research

VANCOUVER, BC, Sept. 19, 2023 /PRNewswire/ -- USA News Group  -  A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT,  Memorial Sloan Kettering Cancer Center and The Rockefeller University. Led by 31-year old Reed Jobs, the new firm dubbed 'Yosemite' appears to be an extension of the legacy left by the founder's father, Steve Jobs, the co-founder of Apple, who died in 2011 from a rare form of pancreatic cancer at the age of only 56. From an investment standpoint, the Global Pancreatic Cancer Market is expected to surpass US$7.4 billion by 2032, growing at a health CAGR of 13.7% along the way. Among the biotech sector's most promising developers of treatments for pancreatic cancer are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Incyte Corporation (NASDAQ:INCY), Mirati Therapeutics, Inc. (NASDAQ:MRTX), and BioNTech SE (NASDAQ:BNTX).

Key Points: 
  • According to the American Cancer Society in its Cancer Facts & Figures 2023 report, the five-year survival rate for pancreatic cancer increased by 1% from the previous year to 12%.
  • In terms of targeting pancreatic cancer, the efforts align with the Pancreatic Cancer Action Network (PanCAN), which has been urging advocates from all 50 US states to call on Congress to increase federal funding for pancreatic cancer research.
  • These tests will be for people who have certain kinds of lung cancer, bowel cancer, pancreatic cancer, and other solid tumors, with Mirati providing Incyte with a drug called Adagrasib to use in the study.
  • The tailored neoantigen pancreatic cancer vaccine from BioNTech invoked an immune response in 50% of patients and prevented relapse.

Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial

Retrieved on: 
Thursday, June 22, 2023
PDAC, Pancreatic cancer, Oncolytics Biotech, AB, MBA, Precision, Trial of the century, ONC, Zou huo ru mo, Patient, SAN, JD, DOI, TSX, MOS, Gemcitabine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ORR, Food, Pharmaceutical industry, Tobacco, Pelareorep

SAN DIEGO, CA and CALGARY, AB, June 22, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced pelareorep has been selected for inclusion as a new investigational treatment in Precision PromiseSM, an innovative adaptive Phase 3 clinical trial. The Precision Promise study is designed to evaluate pelareorep in combination with a checkpoint inhibitor and the chemotherapeutic agents gemcitabine and nab-paclitaxel. If successful, the clinical study is expected to support approval of the studied combination as a treatment for first-line metastatic pancreatic ductal adenocarcinoma (PDAC).  

Key Points: 
  • The Precision Promise study is designed to evaluate pelareorep in combination with a checkpoint inhibitor and the chemotherapeutic agents gemcitabine and nab-paclitaxel.
  • Each investigational therapy is subject to pre-specified interim analyses prior to proceeding to the registrational portion of the trial.
  • "We are delighted at being selected by the Precision Promise panel of experts," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech.
  • Pelareorep's inclusion in Precision Promise is supported by prior clinical data in pancreatic cancer that suggests it synergizes with checkpoint inhibition and chemotherapy.

Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial

Retrieved on: 
Thursday, June 22, 2023
PDAC, Pancreatic cancer, Oncolytics Biotech, AB, MBA, Precision, Trial of the century, ONC, Zou huo ru mo, Patient, SAN, JD, DOI, TSX, MOS, Gemcitabine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ORR, Food, Pharmaceutical industry, Tobacco, Pelareorep

SAN DIEGO, CA and CALGARY, AB, June 22, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced pelareorep has been selected for inclusion as a new investigational treatment in Precision PromiseSM, an innovative adaptive Phase 3 clinical trial. The Precision Promise study is designed to evaluate pelareorep in combination with a checkpoint inhibitor and the chemotherapeutic agents gemcitabine and nab-paclitaxel. If successful, the clinical study is expected to support approval of the studied combination as a treatment for first-line metastatic pancreatic ductal adenocarcinoma (PDAC).  

Key Points: 
  • The Precision Promise study is designed to evaluate pelareorep in combination with a checkpoint inhibitor and the chemotherapeutic agents gemcitabine and nab-paclitaxel.
  • Each investigational therapy is subject to pre-specified interim analyses prior to proceeding to the registrational portion of the trial.
  • "We are delighted at being selected by the Precision Promise panel of experts," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech.
  • Pelareorep's inclusion in Precision Promise is supported by prior clinical data in pancreatic cancer that suggests it synergizes with checkpoint inhibition and chemotherapy.

New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

Retrieved on: 
Thursday, June 8, 2023
PDAC, TNBC, Communication, Chronic lymphocytic leukemia, Precigen, Doctor of Philosophy, Investigational New Drug, GILD, MD, Patient, NYSE, News, Bone marrow, CLL, University, Oncolytics Biotech, Acute lymphoblastic leukemia, DLBCL, NK, Research, MD Anderson Cancer Center, B-cell lymphoma, Gilead, GSK plc, ONC, TSX, PD-1, FDA, Pancreatic cancer, GSK, Gilead Sciences, Trinket, Pela, ALL, Cancer, ACT Biotech Inc, National Cancer Institute, Standard of care, Therapy, ORR, Inflammation, Pelareorep, Triple-negative breast cancer, Cell death, Paclitaxel, Dostarlimab, Mantle cell lymphoma, MCL, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Cryptocurrency, EU, Dragonfly, Agency

VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies. How we arm ourselves in the battle against cancer is rapidly changing, thanks to novel mechanisms giving important results, such as those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Gilead Sciences, Inc. (NASDAQ: GILD), iTeos Therapeutics, Inc. (NASDAQ: ITOS), GSK plc (NYSE: GSK), and Precigen, Inc. (NASDAQ: PGEN).

Key Points: 
  • VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer.
  • A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies.
  • At this year's Future of Oncology Virtual Symposium in early April, Oncolytics was selected to participate in a panel presentation called Novel Mechanisms with Important Readouts.
  • Pelareorep's impacts on cancer are also being researched, including through Oncolytics' first and longest-standing focus on its HR-positive HER2-negative metastatic breast cancer program.

New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

Retrieved on: 
Thursday, June 8, 2023
PDAC, TNBC, Communication, Chronic lymphocytic leukemia, Precigen, Doctor of Philosophy, Investigational New Drug, GILD, MD, Patient, NYSE, News, Bone marrow, CLL, University, Oncolytics Biotech, Acute lymphoblastic leukemia, DLBCL, NK, Research, MD Anderson Cancer Center, B-cell lymphoma, Gilead, GSK plc, ONC, TSX, PD-1, FDA, Pancreatic cancer, GSK, Gilead Sciences, Trinket, Pela, ALL, Cancer, ACT Biotech Inc, National Cancer Institute, Standard of care, Therapy, ORR, Inflammation, Pelareorep, Triple-negative breast cancer, Cell death, Paclitaxel, Dostarlimab, Mantle cell lymphoma, MCL, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Cryptocurrency, EU, Dragonfly, Agency

VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies. How we arm ourselves in the battle against cancer is rapidly changing, thanks to novel mechanisms giving important results, such as those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Gilead Sciences, Inc. (NASDAQ: GILD), iTeos Therapeutics, Inc. (NASDAQ: ITOS), GSK plc (NYSE: GSK), and Precigen, Inc. (NASDAQ: PGEN).

Key Points: 
  • VANCOUVER, British Columbia, June 8, 2023 /PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer.
  • A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies.
  • At this year's Future of Oncology Virtual Symposium in early April, Oncolytics was selected to participate in a panel presentation called Novel Mechanisms with Important Readouts.
  • Pelareorep's impacts on cancer are also being researched, including through Oncolytics' first and longest-standing focus on its HR-positive HER2-negative metastatic breast cancer program.